India takes center stage as biopharma booms

New Jersey may still be America's medicine chest, but India is fast becoming the world's medicine plant. As Big Pharma turns to outsourcing to shed costs--and India's homegrown pharma industry turns out more and more of the world's generic meds--the subcontinent's drug output is growing fast. Some 13 percent growth is expected this year, the New York Times reports, to just over $24 billion. And R&D ops are also growing at a fast pace. Report

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.